Unity Biotechnology announces complete 36-week results from Phase 2b ASPIRE

UNITY Biotechnology (UBX) announced complete 36-week results from the Phase 2b ASPIRE clinical trial of intravitreal UBX1325 in patients with diabetic macular edema who had poor vision despite prior anti-VEGF treatment. The Company previously disclosed 24-week and interim 36-week results from its ASPIRE trial, demonstrating that UBX1325 was non-inferior to aflibercept at most time points through 36 weeks, except for the average of weeks 20 and 24, the primary endpoint. Phase 2b ASPIRE study results from all subjects through 36 weeks: Non-inferior visual gains in Best-Corrected Visual Acuity compared to leading anti-VEGF product; UBX1325 was statistically non-inferior to aflibercept at week 36; UBX1325 generally outperformed aflibercept in subjects who had moderately aggressive disease. Favorable safety and tolerability profile: UBX1325 continues to demonstrate a favorable safety and tolerability profile across multiple clinical studies to date; There have been no cases of intraocular inflammation, retinal artery occlusion, endophthalmitis or vasculitis across multiple studies